According to news reports, Pfizer has reversed its position on the closure of its R&D facility at Sandwich, UK, saving 350 jobs. The company’s inhalation R&D group has operated out of Sandwich and had been in limbo after the company announced in February that it would be closing the site.
Annette Doherty, the new site director at Sandwich, commented: “Pfizer’s retained pharmaceutical sciences operations at Sandwich will maintain a nucleus of industry leading talent, skills and capabilities in science and technology at the site. It will be a key part of my role as site director to support the hard work that is being done to find new uses for the site, and continue to support colleagues through the transition as we proceed with our phased exit of the site.”
Read a UK newspaper report.
